This study investigated relationships between the intake of human milk carbohydrates in the first year of life and infant body composition. Higher total carbohydrate concentrations, including human milk oligosaccharides (HMOs), were associated with increased lean mass and reduced adiposity.
This in vitro study found that specific BMOs could inhibit intestinal cell proliferation and have effects on gut differential processes, indicating BMOs may play a role in gastrointetinal development and maturation.
This review detailed the potential metabolic effects of bovine milk oligosaccharides (BMOs) that may be structurally similar to human milk oligosaccharides (HMOs) and explored the possibility of their industrial production for therapeutic uses.
The authors have identified several HMOs with potent antimicrobial activity against the pathogen Group B Steptococcus, and uncovered the mechanism of action of HMO antimicrobial activity such as by increasing bacterial cell permeability.
This review paper studied the significance of sialylated structures in human milk, such as the 3’-sialyllactose (3’-SL) type of human milk oligosaccharides (HMOs), and how they contribute to newborn protection and development.
This review paper takes reader through the almost 20-year long journey in the research of human milk oligosaccharides (HMOs) in the prevention of necrotizing enterocolitis (NEC), including recent human mother-infant cohort studies that confirmed specific HMOs are associated with lower NEC risk.
This study provided insights on the potential role of bioactive components in human milk such as human milk oligosaccharides (HMOs) and the microbiome in impacting the performance of live, attenuated rotavirus vaccines.